Back to top
more

TG Therapeutics (TGTX)

(Real Time Quote from BATS)

$19.99 USD

19.99
5,277,584

0.00 (0.00%)

Updated Aug 8, 2024 09:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Meet Group (MEET) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.

Sanghamitra Saha headshot

Why These Pharma ETFs Rallied on Thursday

by Sanghamitra Saha

A few pharma ETFs hit a one-month high on Feb 28. Why?

Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.

Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings

by Zacks Equity Research

TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.

HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.

Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings

by Zacks Equity Research

CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.

Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

TG Therapeutics (TGTX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (TGTX) Outperforming Other Medical Stocks This Year?

Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher

by Zacks Equity Research

Canopy Growth (CGC) shares rose more than 11% in the last trading session, amid huge volumes.

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

Nabaparna Bhattacharya headshot

5 Beaten-Down Medical Product Stocks to Rebound in 2019

by Nabaparna Bhattacharya

As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

What's in Store for GW Pharma (GWPH) This Earnings Season?

by Zacks Equity Research

On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.

TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.82% and -5.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate TG Therapeutics (TGTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher

by Zacks Equity Research

TG Therapeutics (TGTX) shares rose nearly 9% in the last trading session, amid huge volumes.

    Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

      Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?

      by Zacks Equity Research

      Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.

        Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options

        by Zacks Equity Research

        Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.

          Are Options Traders Betting on a Big Move in TG Therapeutics (TGTX) Stock?

          by Zacks Equity Research

          Investors in TG Therapeutics, Inc. (TGTX) need to pay close attention to the stock based on moves in the options market lately.

            Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?

            by Zacks Equity Research

            Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock which has high level of implied volatility

              Sweta Killa headshot

              5 Top Performing Stocks of the Best ETF of Q1

              by Sweta Killa

              Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.

                Kevin Matras headshot

                How to Uncover Institutional Buying

                by Kevin Matras

                Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include COLM, NXTM, OCR, OVAS and TGTX.